[5-Fluorouracil (5-FU) concentration in prostatic tissue of rats and in prostatic cancer patients after oral administration of 5-FU].
5-FU has been widely used in the treatment of urogenital cancers. The concentration of orally administered 5-FU was investigated in both the serum and prostate of rats and prostatic cancer patients. In the experimental studies rats were divided into two groups. In rats in group 1 (single administration group), after oral administration of 20 mg/kg/day 5-FU, the 5-FU concentration in serum was 0 at 0 min., 0.916 +/- 0.694 at 10 min., 2.000 +/- 1.159 at 20 min., 1.029 +/- 0.570 at 30 min., 0.119 +/- 0.033 at 60 min., 0.020 +/- 0.020 at 2 hr., 0 at 4 hr. and 0 micrograms/ml at 24 hr.; the 5-FU concentration in prostatic tissue as 0 at 0 min., 0.324 +/- 0.190 at 10 min., 0.843 +/- 0.544 at 20 min., 0.469 +/- 0.252 at 30 min., 0.132 +/- 0.027 at 60 min., 0.094 +/- 0.024 at 2 hr., 0.057 +/- 0.020 at 4 hr. and 0 micrograms/g at 24 hr. In rats in group 2 (daily administration group), 20 mg/kg/day 5-FU was orally administered for seven days. On the seventh day, the 5-FU concentration in serum was 0 at 0 min., 1.877 +/- 0.957 at 10 min., 4.091 +/- 2.184 at 20 min., 1.692 +/- 1.033 at 30 min., 0.345 +/- 0.084 at 60 min., 0.036 +/- 0.019 at 2 hr., 0.005 +/- 0.011 at 4 hr. and 0 micrograms/ml at 24 hr.(ABSTRACT TRUNCATED AT 250 WORDS)
Goya
N
N
Department of Urology, Tokyo Women's Medical College.
Yanagisawa
H
H
Nakamura
R
R
Toma
H
H
D000230:Adenocarcinoma / Q000378:metabolism*; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D005472:Fluorouracil / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D016014:Linear Models; D008297:Male; D011467:Prostate / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D005472:Fluorouracil